Pharmaceutical Research Overview
Psyquit 300 mg Cranialz is a quetiapine preparation specifically formulated for pharmaceutical research applications. Quetiapine is an atypical antipsychotic compound belonging to the dibenzothiazepine class, extensively studied for its receptor binding profiles and pharmacological mechanisms. This research-grade preparation enables investigators at Stroid UK Shop to examine quetiapine’s complex receptor interactions, including antagonism at dopamine D2, serotonin 5-HT2A, and histamine H1 receptors. The 300 mg formulation provides standardised material for analytical studies investigating bioavailability, dissolution characteristics, and pharmaceutical equivalence testing protocols.
Laboratory Applications
Research teams can utilise Psyquit 300 mg for comprehensive pharmaceutical analysis including dissolution testing, bioequivalence studies, and formulation development research. The preparation serves as reference material for analytical method development, enabling validation of HPLC and LC-MS procedures used in pharmaceutical quality control. Investigators studying quetiapine preparations can examine tablet disintegration properties, drug release kinetics, and stability under various environmental conditions. The standardised 300 mg dosage facilitates comparative studies with other quetiapine formulations, supporting research into generic drug development and regulatory submission requirements. Laboratory applications extend to pharmaceutical chemistry research investigating quetiapine’s metabolic pathways and degradation products.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Quetiapine |
| Strength | 300 mg |
| Manufacturer | Cranialz |
| Form | Tablet |
| CAS Number | Verify with supplier |
| Molecular Formula | C₂₁H₂₅N₃O₂S |
| Storage | Room temperature, dry conditions |
Researchers can access additional pharmaceutical compounds through our SARMs collection and peptides range for comprehensive drug discovery programmes. Each preparation undergoes quality assessment to ensure consistency for analytical research protocols.
Research Use Compliance
Psyquit 300 mg Cranialz is supplied strictly for in-vitro research and analytical testing purposes only. This product is not intended for human consumption, clinical use, or therapeutic applications. Researchers must ensure compliance with applicable pharmaceutical research regulations and maintain appropriate laboratory safety protocols when handling this material. All investigations should be conducted in properly equipped analytical facilities with trained personnel familiar with pharmaceutical research methodologies.
